Actinogen Medical Limited · ASX:ACW
Actinogen Medical — Shareholder Meeting (November 2012)
37 slides from Actinogen Medical's shareholder meeting presentation, Nov 28, 2012
Slide 1: David Keast
For personal use only David Keast
Slide 2: 2011-2012: A Year of Consolidation
For personal use only 2011-‐2012 : A YEAR OF CONSOLIDATION
Slide 3: Field sampling reduced as R&D approaches detailed trials
For personal use only Field sampling has been reduced as a result of some of Actinogen’s R&D approaching the need for detailed trials in preparation for seeking commercialisation
Slide 4: Areas of research
For personal use only [1] Cancer cell screening [2] Agriculture/horticulture [3] Cellulase & bioethanol [4] Antibiotics [5] Special project { Shikimic acid}
Slide 5: Acquisition of Celgenics
For personal use only Actinogen acquired Celgenics in September 2011. Celgenics was a company dedicated to the discovery and isolation of soil actinomycetes with bioactive molecules directed to a recently discovered set of cancer cells known as the Cancer Stem Cells (CSC).
Slide 6: Cancer stem cells
For personal use only The CSCs are a small number of cells (1-‐2%) now thought to exist in most cancers. They share some properties with embryonic stem cells. They can be detected by characteristic markers on their cell surfaces especially one named the CD133 marker. They are thought to be largely
Slide 7: Targeting cancer stem cells
For personal use only New agents are required to specifically target these cells Actinogen is applying its expertise to the discovery of such agents from the actinomycetes. New highly specialised equipment has recently been installed at the QE II Medical Centre that can aid in this area and Actinogen
Slide 8: An example of results
For personal use only An example of results CD133+ = 0% Enrichment of CSC using Actinogen’s CD133+ = 23.40% techniques
Slide 9: U125MG brain tumour cell results
For personal use only 120 U125MG cells brain tumour % live cells Illustration 100 % CD133+ live cells 80 60 of some results of treatments overall to % 40 20 enrich for CSCs 0 U125MG U125MG + U125MG + U125MG NSC U125MG NSC -‐20 Carbo. ST Carbo. LT + Carbo. LT U125MG cells ST short term: LT long term
Slide 10: Agriculture/horticulture programs
For personal use only {A}: Plant hormones {B] Salt tolerant actinomycetes {C} Biofumigation
Slide 11: Results from 2010-2011
For personal use only From 2010-‐2011 results TOTAL BEAN WEIGHT {GMS @ D45} 70 60 50 40 GMS 30 20 10 Water Medium 1503 1487 0 WET WEIGHT
Slide 12: For personal use only
For personal use only Water medium 1503 1487 Water Medium 1503 1487
Slide 13: Field trial and government approvals
For personal use only A further larger field trial is in progress using newly planted young commercial olive trees. Results should become available over 2012-‐2013. Actinogen is currently awaiting government approvals needed before being eligible for commercialisation. Once government approval has b
Slide 14: Outline: soil salinity problem
For personal use only OUTLINE Worldwide problem involving millions of hectares. Increasing economic problems throughout Australia through loss of broad acre farmlands
Slide 15: Important elements of soil fertility
For personal use only Important elements of soil fertility HUMUS The natural soil fertility cycle is dependent on the availability of natural nutrients largely from humus production Humus supplied by the soil micro-‐flora and fauna. Although their biomass is only 1-‐5% it is their rapid turnover ev
Slide 16: Soil rehabilitation programmes
For personal use only In all soil rehabilitation programmes it is essential to rebuild a viable fertility cycle through the soil microflora. A salt tolerant microflora is the first essential to begin to rebuild the humus and encourage three important elements:
Slide 17: Salt tolerant actinomycetes
For personal use only Actinogen now knows that some of the salt tolerant actinomycetes that it has selected produce cellulase while others produce anti fungal agents. Both of these properties should aid in soil rehabilitation processes. Now moving to field trials and marketing
Slide 18: Actinomycetes producing volatile anti fungal agents
For personal use only The use of actinomycetes that produce volatile anti fungal agents Actinogen’s concept : Replace current chemical fungicides with spraying actinomycetes producing volatile anti fungal agents The bacteria filter through the upper biomass and establish underneath to allow their vol
Slide 19: Testing against plant pathogenic fungi
For personal use only This is used against a panel of five common plant pathogenic fungi with isolates already indicating that volatile ( polyenes) are being produced No added 1week after actino 3weeks later actino isolate placed around fungi
Slide 20: Current trials
For personal use only Current trials {1}: Final Proof Actinomycete of volatile product Pathogenic plant fungus The volatile {polyene}
Slide 21: Cellulase and Biofuel
For personal use only [3]: Cellulase and Biofuel Electron microscopy Paper structure Paper after actinomycetes digestion
Slide 22: The CCRA screening assay
For personal use only The CCRA screening assay This is a simple diffusion screening assay As cellulase diffuses through the coloured agar it digests the cellulose which leads to clear zones
Slide 23: Diameter of zone of clearing (cm)
For personal use only Commercial cellulases were titrated against an actinomycete ACN 4205 5 Diamater of zone of clearing (cm) 4 y = 0.4383ln(x) + 3.7529 y y == 00.4316ln(x) .5017ln(x) ++ 33.4956 .3789 3 y = 0.377ln(x) + 3.1001 y = 0.4937ln(x) + 2.3719 2 y = 0.4045ln(x) + 2.0072 1 0 0.01 0.1 1 Dilut
Slide 24: Results confirmed in larger fermentation vessels
For personal use only Actinogen’s results were confirmed and cultural conditions optimised using larger fermentation vessels up to 10 litres.
Slide 25: Cellulase Fermentations
For personal use only Cellulase Fermentations
Slide 26: Cellulase activities in 2-litre fermentations
For personal use only Figure 2: Cellulase activities in the supernatants from the 2-‐litre fermentations. Yield is expressed as amount of reducing sugar produced in the cellulase assay, as determined by incubation with DNS reagent, measurement of absorbance at 540 nm, and plotting a standard curve
Slide 27: Second Generation Bioethanol
Second Generation For personal use only BIOETHANOL Its production Biowastes: Distribution Domestic Industrial New Yeasts Enzyme BIOETHANOL hydrolysis Fermentation Pretreatments Waste
Slide 28: Actinogen's programme
For personal use only Actinogen’s programme
Slide 29: Currently three areas of interest
For personal use only Currently three areas of interest {a}: MRSA: antibiotic resistant golden Staphylococci {b}:Anti Clostridium difficile {c} Anti Candida agents
Slide 30: MRSA
For personal use only {a}: MRSA Actinogen currently has 19 actinomycetes that are producing antibiotic molecules that are different from all antibiotics that we can screen for through our dereplication libraries. Shortly these active molecules will be prepared to go to larger library testing; any tha
Slide 31: Clostridium difficile
For personal use only {b}: Clostridium difficile: This is an anaerobic bacterium that is one of the newer so called emerging pathogens. It causes lethal diarrhoea, through toxins that it produces and is now significant for both man and many commercial farm animals. It lives in the gut and current antib
Slide 32: Anti Candida antibiotic
For personal use only {c}: Anti Candida antibiotic: Candida infections from several species are important when the immune system is depressed. This occurs following:-‐ organ transplants, AIDS, with increasing age, and in conditions such as oral and vaginal thrush in children and in adults.. Actinog
Slide 33: Shikimic acid discovery
For personal use only Actinogen has discovered an actinomycete that synthesizes shikimic acid the organic acid which forms the basis for the construction of Tamiflu. Current methods of obtaining this acid are extremely expensive and time consuming and there is always an under supply.
Slide 34: Shikimic acid culture medium profile
For personal use only Shikimic acid The culture medium profile for isolate 1488
Slide 35: Ultra violet profiles of shikimic acid
For personal use only The ultra violet profiles of pure shikimic acid(blue) and that from isolate 1488 (red).
Slide 36: Shikimic acid trials
For personal use only This is an exciting new development. Trials are in place to: (i): obtain the shikimic acid as pure as possible to confirm its structure by Mass Spectrometry. (ii): determine the amount of shikimic acid that is being produced. This will allow preliminary costings. (iii):Purify th
Slide 37: Thank you
For personal use only Actinogen is now in an exciting phase of its development with a series of its projects close to or ready for commercialisation. Thankyou
Actinogen Medical — Shareholder Meeting (November 2012) on 6ix